UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 12, 2019

Medidata Solutions, Inc.
(Exact name of registrant as specified in its charter)

Delaware
 
001-34387
 
13-4066508
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)

Registrant’s telephone number, including area code: (212) 918-1800
350 Hudson Street, 9th Floor
New York, New York
 
10014
(Address of principal executive offices)
 
(Zip Code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2 below):

¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.02.    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(e) Compensatory Arrangements of Certain Officers
On February 12, 2019, the compensation committee (the “Committee”) of the board of directors of Medidata Solutions, Inc. (the “Company”) approved the following compensatory arrangements for its named executive officers.
2018 Annual Cash Bonuses . The Committee determined the annual cash bonus awards for 2018 for each of the Company’s named executive officers, based on its assessment of achievement of the 2018 performance targets, as follows: Tarek Sherif (Chairman and Chief Executive Officer)—$605,775; Glen de Vries (President)—$605,775; Rouven Bergmann (Chief Financial Officer)— $464,531; Michael Otner (EVP & General Counsel)—$200,475; and Michael Pray (EVP, Global Sales)—$406,181.
2019 Salaries and Bonus Targets . The Committee approved 2019 salaries and target cash bonus amounts for the Company’s named executive officers. The 2019 cash bonuses will be determined by the Committee based on achievement of the following factors: (i) the Chief Executive Officer and President—100% corporate financial performance objectives (revenue and EBITDAO); (ii) the Chief Financial Officer—75% on the company performance objectives and 25% based on individual performance objectives; (iii) EVP & General Counsel—50% on the company performance objectives and 50% based on individual performance objectives; and (iv) EVP, Global Sales —25% on the company performance objectives, 50% based on sales performance objectives (global iACV achievement), and 25% based on individual performance objectives.
The table below sets forth the 2019 salaries and target cash bonus amounts of the Company’s named executive officers:
Name
 
Office
 
2019 Salary
 
2019 Bonus Target
Tarek Sherif
 
Chairman and Chief Executive Officer
 
$
639,600

 
$
639,600
 
Glen de Vries
 
President
 
$
639,600

 
$
639,600
 
Rouven Bergmann
 
Chief Financial Officer
 
$
520,000

 
$
390,000
 
Michael Otner
 
EVP & General Counsel
 
$
374,400

 
$
187,200
 
Michael Pray
 
EVP, Global Sales
 
$
431,600

 
$
431,600
 

2019 Equity Awards . The Committee approved equity awards for 2019 pursuant to the Amended and Restated 2017 Long-Term Incentive Plan, with 50% of such awards being in the form of shares of restricted stock with time-based vesting, and 50% of such awards being in the form of restricted stock units with performance-based vesting (“PBRSUs”), except for Messrs. Sherif and de Vries who received 35% of such awards in the form of shares of restricted stock with time-based vesting and 65% of such awards in the form of PBRSUs.
The shares of restricted stock will vest annually over a four-year period from grant, 25% on the first anniversary of the grant date and each of the next three annual anniversaries of the grant date ( i.e ., one-fourth of the shares will vest on each of February 12, 2020, February 12, 2021, February 12, 2022, and February 12, 2023), subject to continued employment with the Company.



Vesting of one half of the PBRSUs will be based on the Company’s achievement of performance goals based on the Company’s Revenue Attainment over a three-year performance period ending December 31, 2021 with the number of shares to be actually earned capped at 250% of the target amount (in accordance with the illustrative models for over-performance and under-performance in comparison to the Company’s targets that were reviewed by the Committee). Vesting of the other half of the PBRSUs will be based on the Company’s total stockholder return (“TSR”) relative to the TSR of companies in the Russell 2000 Index over a three-year performance period ending December 31, 2021 with the number of shares to be actually earned capped at 200% of the target amount (in accordance with the illustrative models for over-performance and under-performance in comparison to the Company’s targets that were reviewed by the Committee).
The table below sets forth the 2019 awards of restricted stock and PBRSUs awarded to the following named executive officers:
Name
 
Office
 
 
 
Number of PBRSUs
 
 
Number of
Shares of
Restricted
Stock
 
2019-2021  
Revenue Attainment  
(50%)
 
2019-2021  
Relative
TSR
 
(50%)
Tarek Sherif
 
Chairman and Chief Executive Officer
 
40,633

 
37,730
 
37,731
Glen de Vries
 
President
 
40,633

 
37,730
 
37,731
Rouven Bergmann
 
Chief Financial Officer
 
25,395

 
12,697
 
12,698
Michael Otner
 
EVP & General Counsel
 
12,698

 
6,349
 
6,349
Michael Pray
 
EVP, Global Sales
 
18,140

 
9,070
 
9,070

Supplemental Award to Chief Financial Officer . The Committee approved a supplemental restricted stock award of 7,256 shares of restricted stock to Rouven Bergmann (Chief Financial Officer) pursuant to the Amended and Restated 2017 Long-Term Incentive Plan. The shares shall vest annually over a two-year period from grant, 50% on the first anniversary of the grant date and 50% on the second anniversary of the grant date ( i.e ., one-half of the shares will vest on each of February 12, 2020 and February 12, 2021).



SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
MEDIDATA SOLUTIONS, INC.
 
Date: February 15, 2019
 
By:
 
/s/ MICHAEL I. OTNER
Name:
 
Michael I. Otner
Title:
 
Executive Vice President, General Counsel and Secretary


Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Medidata Solutions Charts.
Medidata Solutions (NASDAQ:MDSO)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Medidata Solutions Charts.